Despite a recent -6.6% monthly decline contrasting with the S&P 500's +2.7% gain, Tenet Healthcare (THC) has received a Zacks Rank #1 (Strong Buy). This rating is driven by significant upward revisions in consensus earnings estimates, with current quarter EPS estimates rising 26% and current fiscal year estimates up 24.9% over the past 30 days. The hospital operator also boasts a history of consistently beating EPS estimates and is currently graded 'A' for value, indicating it trades at a discount to peers, suggesting potential for near-term outperformance.
Tenet Healthcare (THC) presents a notable disconnect between its recent market performance and its fundamental outlook. Over the past month, the stock has declined by 6.6%, significantly underperforming both the S&P 500 composite's 2.7% gain and its own industry's 7.6% loss. However, this price weakness is contradicted by a powerful trend in upward earnings estimate revisions from sell-side analysts. The consensus earnings estimate for the current fiscal year has been revised upward by 24.9% over the last 30 days to $14.92, representing a 25.6% year-over-year growth projection. Similarly, the current quarter's estimate has increased by 26% in the same period. This optimism is supported by a strong track record of execution, with the company beating consensus EPS estimates in each of the last four quarters, including a significant 41.55% surprise in the most recent reporting period. While projected revenue growth is more modest, at 2.1% for the current fiscal year and 4.6% for the next, the company's valuation appears attractive, as indicated by its Zacks Value Style Score of 'A', suggesting it trades at a discount relative to its peers. The combination of these factors has resulted in a Zacks Rank #1 (Strong Buy), signaling potential for near-term outperformance.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
